ACADIA Pharmaceuticals Inc (ACAD)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Session momentumUp 2.9% on the session+5
- QualityRevenue growing 47% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst is analyst-driven, with multiple price target hikes reinforcing positive sentiment. The continuation probability is moderate, around 55–65%, as the stock may drift higher but could fade without fresh fundamental news. Informational only — not financial advice.
- Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38Benzinga · 2026-08-25
- Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28Benzinga · 2026-08-25
- Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40Benzinga · 2026-08-25
- Acadia Pharmaceuticals: Another Bite At The Alzheimer's AppleSeekingAlpha · 2026-08-24
- UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49Benzinga · 2026-08-17
Any AI summary is an interpretation of public news, not advice or a price target.